Research and Markets has announced the addition of the "Global Prostate Cancer Drugs Market 2016-2020" report to their offering.
The report forecasts the global prostate cancer drugs market to grow at a CAGR of 9.21% during the period 2016-2020.
According to CDC, it is one of the leading cause of cancer deaths in men across the US. According to the Urology Care Foundation, globally, one in seven men will be diagnosed with the disease. Growth in the prostate can be benign or malignant. It's estimated that about one in 35 men die due to prostate cancer.
The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
The market has been witnessing a growing popularity for targeted therapies and immunotherapies, owing to their specific mechanism of action. Immunotherapies such as vaccines, and immune checkpoint inhibitors are gaining traction in the market driven by their limited side-effects, and high efficacy.
Key vendors:
- AbbVie
- Astellas Pharma
- AstraZeneca
- Johnson & Johnson
-
Sanofi
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Disease overview
Part 06: Pipeline analysis
Part 07: Market landscape
Part 08: Market segmentation by therapy
Part 09: Geographical segmentation
Part 10: Market drivers
Part 11: Impact of drivers
Part 12: Market challenges
Part 13: Impact of drivers and challenges
Part 14: Market trends
Part 15: Vendor landscape
Part 16: Key vendor analysis
Part 17: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/ztx43f/global_prostate
View source version on businesswire.com: http://www.businesswire.com/news/home/20170104005690/en/